Tests MK-2870 alone or with other drugs for gastrointestinal cancers
Tests MK-2870 in adults with advanced bowel, pancreas or bile duct cancer.
Plain-language title generated from the registry record
Registry title: A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Key facts
- Where
- Milan and Rome, ItalySee the 3 sites
- Phase
- Phase 1/2
Where in Italy
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT06428409EU 2023-508703-21-00
- Record updated
- 29 October 2026
- Original description
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:Read full original descriptionShow less
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:
* About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Inclusion: The main inclusion criteria include but are not limited to the following:; Has one of the following cancers:; Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer; Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer; Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer; Advanced and/or unresectable BTC and has not received prior therapy for the cancer; For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment.
Exclusion: For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention; History of severe eye disease; History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening; The main exclusion criteria include but are not limited to the following:.